Why the study?
Pediatric hypertension management remains challenging due to limited safety and efficacy trials, pharmacokinetics, and unknown risks of prolonged exposure, prompting a review of safety and efficacy literature for commonly prescribed antihypertensive agents.
While ACE-I, ARBs, and CCBs have the most data supporting their use in pediatric hypertension, significant gaps remain regarding long-term safety and the use of other antihypertensive classes.
Answers are grounded in this paper and cite their sources.
Supports ACE-I/ARB/CCB selection in pediatric hypertension per current data; leaves open trials on beta-blockers, vasodilators, and long-term safety.
Recently updated clinical guidelines have highlighted the gaps in our understanding and management of pediatric hypertension. With increased recognition and diagnosis of pediatric hypertension, the use of antihypertensive agents is also likely to increase. Drug selection to treat hypertension in the pediatric patient population remains challenging. This is primarily due to a lack of large, well-designed pediatric safety and efficacy trials, limited understanding of pharmacokinetics in children, and unknown risk of prolonged exposure to antihypertensive therapies. With newer legislation providing financial incentives for conducting clinical trials in children, along with publication of pediatric-focused guidelines, literature available for antihypertensive agents in pediatrics has increased over the last 20 years. The objective of this article is to review the literature for safety and efficacy of commonly prescribed antihypertensive agents in pediatrics. Thus far, the most data to support use in children was found for angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), and calcium channel blockers (CCB). Several gaps were noted in the literature, particularly for beta blockers, vasodilators, and the long-term safety profile of antihypertensive agents in children. Further clinical trials are needed to guide safe and effective prescribing in the pediatric population.
No takes yet. Share an insight, caveat, or question.
Siddiqi et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: